Semaglutide approval delays in Brazil
Brazil approval for semaglutide is delayed by 3-4 months, which could impact FY27 unit sales guidance of 12 million units.
DRREDDY / Q4-FY26 / risks
Keep the risk register visible.
Dr. Reddy's Laboratories · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
medium
Lenalidomide shelf-stock adjustment recurrence
A surprise INR 453 crore shelf-stock adjustment hit Q4 revenue; similar customer-driven adjustments could recur.
U.S. generics price erosion
U.S. generics revenue has been flat despite new launches, indicating significant price erosion that may continue.
CAR T and partnered asset discontinuation
Impairment of INR 135 crore on CAR T and INR 93 crore on partnered asset (Immutep) highlights R&D pipeline risk.